What top creators are saying about Kodiak Sciences Inc.(KOD)

The speaker is skeptical of the clinical evidence and reimbursement prospects for Kodiak's drugs but acknowledges potential commercial revenue and a speculative short-term rebound. Buying during a decline carries substantial risk.

Kodiak was mentioned alongside Liquidia as part of a one-two punch of losses, with no further company-specific analysis.

The speaker called the stock overvalued and described it as part of a losing trade, while acknowledging uncertainty about when investors might recover their money.

Briefly described as down on the day, with no company-specific news, investment thesis, or recommendation.

The speaker held a small short position ahead of a high-risk binary event and noted the company's limited cash.

The stock was noted as down, but no explanation or recommendation was provided.

The speaker retained a bearish fundamental view, questioning the clinical evidence and product differentiation, but acknowledged that meaningful sales and heavy short interest contributed to a sharp stock rise.

The speaker viewed the trial data as poor and considered the stock overvalued around $85, while warning that shorting a rapidly rising stock carries squeeze risk.

The host was bearish on the clinical data, re-established a short position, and questioned whether the drug candidates could compete with Eylea. They also warned that crowded short interest and squeeze risk make the trade difficult.

Positive Daybreak trial results suggest a potentially differentiated durability profile for its wet AMD program, but commercial uptake, payer access, and durability in previously treated patients remain uncertain.

The speaker was strongly bearish ahead of clinical results, citing doubts about the drug's efficacy versus Eylea, trial design, and prospects for FDA acceptance.

The speaker was strongly bearish, arguing that KSI-501 has not shown an advantage over Eylea despite a more burdensome dosing regimen. They anticipated another trial failure and said they were considering shorting more shares.

The speaker said he was short Kodiak and expected it to fail, comparing it to a version of Eylea, but provided no evidence or timeline.

The speaker was short ahead of trial data and strongly skeptical of the eye-disease drug's benefit, trial design, and dosing burden. He described the event as highly binary, acknowledged less than a 1% chance of a dramatic upside outcome, and had not finalized whether to change the position.

Shkreli viewed Kodiak as a high-risk binary event, thought a result might fail, and noted limited cash. He said his short position was small and was concerned about the timing of a possible announcement.

The speaker was bearish, citing the discontinuation of tarcocimab, prior trial failures, and concerns that the company was repeating a similar approach.

Speaker expressed surprise that the company is still active despite previous clinical setbacks.